The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
A Biodegradable Nanoparticle Platform for the Induction of Antigen-Specific Immune Tolerance for Treatment of Autoimmune Disease
Open accessAbstract
Targeted immune tolerance is a coveted therapy for the treatment of a variety of autoimmune diseases, as current treatment options often involve nonspecific immunosuppression. Intravenous (iv) infusion of apoptotic syngeneic splenocytes linked with peptide or protein autoantigens using ethylene carbodiimide (ECDI) has been demonstrated to be an effective method for inducing peripheral, antigen-specific tolerance for treatment of autoimmune disease. Here, we show the ability of biodegradable poly(lactic-co-glycolic acid) (PLG) nanoparticles to function as a safe, cost-effective, and highly efficient alternative to cellular carriers for the induction of antigen-specific T cell tolerance. We describe the formulation of tolerogenic PLG particles and demonstrate that administration of myelin antigen-coupled particles both prevented and treated relapsing-remitting experimental autoimmune encephalomyelitis (R-EAE), a CD4 T cell-mediated mouse model of multiple sclerosis (MS). PLG particles made on-site with surfactant modifications surpass the efficacy of commercially available particles in their ability to couple peptide and to prevent disease induction. Most importantly, myelin antigen-coupled PLG nanoparticles are able to significantly ameliorate ongoing disease and subsequent relapses when administered at onset or at peak of acute disease, and minimize epitope spreading when administered during disease remission. Therapeutic treatment results in significantly reduced CNS infiltration of encephalitogenic Th1 (IFN-γ) and Th17 (IL-17a) cells as well as inflammatory monocytes/macrophages. Together, these data describe a platform for antigen display that is safe, low-cost, and highly effective at inducing antigen-specific T cell tolerance. The development of such a platform carries broad implications for the treatment of a variety of immune-mediated diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lundqvist, M., Stigler, J., Elia, G., Lynch, I., Cedervall, T., & Dawson, K. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805135105 · Cited by 2,823
Role of target geometry in phagocytosis
Champion, J. A., & Mitragotri, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600997103 · Cited by 2,074
Immunological properties of engineered nanomaterials
Dobrovolskaia, M. A., & McNeil, S. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.223 · Cited by 1,823
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L., & Karin, N. (1992) · Nature · doi:10.1038/356063a0 · Cited by 1,737
Kuchroo, V. K., Prabhu Das, M., Brown, J. A., Ranger, A. M., Zamvil, S. S., Sobel, R. A., Weiner, H. L., Nabavi, N., & Glimcher, L. H. (1995) · Cell · doi:10.1016/0092-8674(95)90349-6 · Cited by 1,641
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Miller, D. H., Khan, O. A., Sheremata, W. A., Blumhardt, L. D., Rice, G. P. A., Libonati, M. A., Willmer-Hulme, A. J., Dalton, C. M., Miszkiel, K. A., & O'Connor, P. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020696 · Cited by 1,242
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Jenkins, M. K., & Schwartz, R. H. (1987) · The Journal of experimental medicine · doi:10.1084/jem.165.2.302 · Cited by 1,170
Kleinschmidt-DeMasters, B. K., & Tyler, K. L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051782 · Cited by 1,072
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., & Pelletier, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051847 · Cited by 1,034
Sahoo, S. K., Panyam, J., Prabha, S., & Labhasetwar, V. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00127-x · Cited by 990
Minimal "Self" Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles
Rodriguez, P. L., Harada, T., Christian, D. A., Pantano, D. A., Tsai, R. K., & Discher, D. E. (2013) · Science · doi:10.1126/science.1229568 · Cited by 985
Bielekova, B., Goodwin, B., Richert, N., Cortese, I., Kondo, T., Afshar, G., Gran, B., Eaton, J., Antel, J., Frank, J. A., et al. (2000) · Nature Medicine · doi:10.1038/80516 · Cited by 823
Jäger, A., Dardalhon, V., Sobel, R. A., Bettelli, E., & Kuchroo, V. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901906 · Cited by 783
Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis
McMahon, E. J., Bailey, S. L., Castenada, C. V., Waldner, H., & Miller, S. D. (2005) · Nature Medicine · doi:10.1038/nm1202 · Cited by 694
Self-citationRuddle, N. H., Bergman, C. M., McGrath, K. M., Lingenheld, E. G., Grunnet, M. L., Padula, S. J., & Clark, R. B. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.4.1193 · Cited by 688
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
Chatenoud, L., Thervet, E., Primo, J., & Bach, J. F. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.1.123 · Cited by 664
Belghith, M., Bluestone, J. A., Barriot, S., Mégret, J., Bach, J.-F., & Chatenoud, L. (2003) · Nature Medicine · doi:10.1038/nm924 · Cited by 586
Karpus, W. J., Lukacs, N. W., McRae, B. L., Strieter, R. M., Kunkel, S. L., & Miller, S. D. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.10.5003 · Cited by 482
Self-citationBailey, S. L., Schreiner, B., McMahon, E. J., & Miller, S. D. (2007) · Nature Immunology · doi:10.1038/ni1430 · Cited by 463
Self-citationCD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice
Chatenoud, L., Primo, J., & Bach, J. F. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.6.2947 · Cited by 417
An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis
Nicholson, L. B., Greer, J. M., Sobel, R. A., Lees, M. B., & Kuchroo, V. K. (1995) · Immunity · doi:10.1016/1074-7613(95)90169-8 · Cited by 412
Getts, D. R., Martin, A. J., McCarthy, D. P., Terry, R. L., Hunter, Z. N., Yap, W. T., Getts, M. T., Pleiss, M., Luo, X., King, N. J., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2434 · Cited by 392
Self-citationWraith, D. C., Smilek, D. E., Mitchell, D. J., Steinman, L., & McDevitt, H. O. (1989) · Cell · doi:10.1016/0092-8674(89)90287-0 · Cited by 389
Therapeutic Inflammatory Monocyte Modulation Using Immune-Modifying Microparticles
Getts, D. R., Terry, R. L., Getts, M. T., Deffrasnes, C., Müller, M., van Vreden, C., Ashhurst, T. M., Chami, B., McCarthy, D., Wu, H., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007563 · Cited by 378
Self-citationScavenger receptors: role in innate immunity and microbial pathogenesis
Areschoug, T., & Gordon, S. (2009) · Cellular Microbiology · doi:10.1111/j.1462-5822.2009.01326.x · Cited by 317
Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE
Miller, S. D., Vanderlugt, C. L., Lenschow, D. J., Pope, J. G., Karandikar, N. J., Dal Canto, M. C., & Bluestone, J. A. (1995) · Immunity · doi:10.1016/1074-7613(95)90063-2 · Cited by 315
Self-citationYeste, A., Nadeau, M., Burns, E. J., Weiner, H. L., & Quintana, F. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120611109 · Cited by 302
Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease
Miller, S. D., Turley, D. M., & Podojil, J. R. (2007) · Nature Reviews Immunology · doi:10.1038/nri2153 · Cited by 290
Self-citationLutterotti, A., Yousef, S., Sputtek, A., Stürner, K. H., Stellmann, J.-P., Breiden, P., Reinhardt, S., Schulze, C., Bester, M., Heesen, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006168 · Cited by 281
Self-citationVanderlugt, C. L., Neville, K. L., Nikcevich, K. M., Eagar, T. N., Bluestone, J. A., & Miller, S. D. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.2.670 · Cited by 213
Self-citationMcCarthy, D. P., Richards, M. H., & Miller, S. D. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-60761-720-4_19 · Cited by 208
Self-citationGetts, D. R., Turley, D. M., Smith, C. E., Harp, C. T., McCarthy, D., Feeney, E. M., Getts, M. T., Martin, A. J., Luo, X., Terry, R. L., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1004175 · Cited by 198
Self-citationChong, C. S. W., Cao, M., Wong, W. W., Fischer, K. P., Addison, W. R., Kwon, G. S., Tyrrell, D. L., & Samuel, J. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.09.014 · Cited by 191
Tompkins, S. M., Padilla, J., Dal Canto, M. C., Ting, J. P.-Y., Van Kaer, L., & Miller, S. D. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.8.4173 · Cited by 190
Self-citationKohm, A. P., Williams, J. S., Bickford, A. L., McMahon, J. S., Chatenoud, L., Bach, J., Bluestone, J. A., & Miller, S. D. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4525 · Cited by 145
Self-citationKennedy, M., Tan, L., Canto, M. C. D., Tuohy, V. K., Lu, Z. J., Trotter, J. L., & Miller, S. D. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.3.909 · Cited by 140
Self-citationImmunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?
Luo, X., Herold, K. C., & Miller, S. D. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.002 · Cited by 139
Self-citationSynthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity
Nixon, D. F., Hioe, C. E., Chen, P., Bian, Z., Kuebler, P., Li, M.-L., Qiu, H., Li, X.-M., Singh, M., Richardson, J. L., et al. (1996) · Vaccine · doi:10.1016/s0264-410x(96)00099-0 · Cited by 133
Turley, D. M., & Miller, S. D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2212 · Cited by 126
Self-citationSmith, C., Eagar, T. N., Strominger, J. L., & Miller, S. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504131102 · Cited by 94
Self-citationBiodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses
Lutsiak, M. E. C., Kwon, G. S., & Samuel, J. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.6.0004 · Cited by 89
Autoimmunity versus tolerance: Can dying cells tip the balance?
Viorritto, I. C. B., Nikolov, N. P., & Siegel, R. M. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.07.012 · Cited by 82
Biodegradable Microspheres with Enhanced Capacity for Covalently Bound Surface Ligands
Keegan, M. E., Falcone, J. L., Leung, T. C.-Y., & Saltzman, W. M. (2004) · Macromolecules · doi:10.1021/ma049470u · Cited by 74
Engineering DNA Nanoparticles as Immunomodulatory Reagents that Activate Regulatory T Cells
Huang, L., Lemos, H. D. P., Li, L., Li, M., Chandler, P., Baban, B., McGaha, T. L., Ravishankar, B., Lee, J. R., Munn, D. H., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103668 · Cited by 71
Tan, L., Kennedy, M., & Miller, S. D. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.9.2748 · Cited by 65
Self-citationBatanero, E., Barral, P., Villalba, M., & Rodríguez, R. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(01)00497-5 · Cited by 15
Monoclonal antibodies in neuroinflammatory diseases
Klotz, L., & Wiendl, H. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.767329 · Cited by 15
Rituximab and Multiple Sclerosis
Kitsos, D. K., Tsiodras, S., Stamboulis, E., & Voumvourakis, K. I. (2012) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31824523c9 · Cited by 13
Cited by
Synthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 763
Cell membrane-derived nanomaterials for biomedical applications
Fang, R. H., Jiang, Y., Fang, J. C., & Zhang, L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.02.041 · Cited by 468
Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., & Martinez-Chapa, S. O. (2020) · ACS Nano · doi:10.1021/acsnano.0c04006 · Cited by 385
Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 259
Liu, J., Liu, Z., Pang, Y., & Zhou, H. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01343-7 · Cited by 219
Metadata
- Authors
- Hunter, Z., McCarthy, D. P., Yap, W. T., Harp, C. T., Getts, D. R., Shea, L. D., & Miller, S. D.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-02-27
- Volume
- 8
- Issue
- 3
- Pages
- 2148-2160
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2324016220
- Cited by
- 301
- References
- 49
- FWCI
- 10.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.